Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience

Abstract

Background and aims: Accurate estimates of the long-term risks of adverse outcomes after transjugular intrahepatic portosystemic shunt (TIPS) treatment are needed. The aim of this cohort study was to estimate the risks of stent dysfunction, variceal bleeding, refractory ascites, hepatic encephalopathy (HE), and death after TIPS treatment.Methods: We extracted data from electronic medical records of 104 consecutive TIPS patients. Gore® Viatorr® TIPS endoprostheses were used in all patients. We conducted competing risks analysis of the risk of stent dysfunction and variceal bleeding, and Kaplan–Meier estimation of overall survival.Results: The overall 1-year survival after TIPS insertion was 82% (95% confidence interval [CI]: 73–88%), and the 1-year risk of stent dysfunction was 15% (95% CI: 9–22%). In patients who had a TIPS for variceal bleeding, the 1-year risk of rebleeding was 23% (95% CI: 13–35%). In patients who had a TIPS for refractory ascites, the risk of having an unsuccessful ascites outcome 1 year after TIPS for refractory ascites was 35% (95% CI: 21–52%). Overall, the 1-year risk of overt HE was 38% (95% CI: 32–43%). The risk of experiencing any of the defined complications during the first year was 56% (95% CI: 45–66%).Conclusion: TIPS is an effective treatment for variceal bleeding and refractory ascites in most cases, but more than half of the patients experience either death, stent dysfunction, recurrence of symptoms, or overt HE within the first year after the procedure.